Drug Search Results
More Filters [+]

ASP-6282

Alternative Names: asp-6282, asp6282, asp 6282
Latest Update: 2016-07-01
Latest Update Note: Clinical Trial Update

Product Description

Astellas Pharma was developing asp-6282, an oral drug, for the treatment of underactive bladder (Sourced from: https://www.astellas.com/system/files/news/2018-03/20150527_Eg.pdf)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-6282

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

First-in-human

P1

Completed

Healthy Volunteers

2016-05-01

Recent News Events

Date

Type

Title